Unicycive Therapeutics, Inc.
UNCY
$5.09
$0.061.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.24% | 37.77% | 68.40% | 89.81% | 90.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.79% | -3.03% | -8.10% | 8.18% | 5.57% |
| Operating Income | -8.79% | 3.03% | 8.10% | -8.18% | -5.57% |
| Income Before Tax | -11.83% | -162.89% | 27.70% | -45.26% | -35.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.83% | -162.89% | 27.70% | -45.26% | -35.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.83% | -162.89% | 27.70% | -45.26% | -35.54% |
| EBIT | -8.79% | 3.03% | 8.10% | -8.18% | -5.57% |
| EBITDA | -8.78% | 3.07% | 8.14% | -8.14% | -5.53% |
| EPS Basic | 45.67% | -240.83% | 76.37% | 56.42% | 59.92% |
| Normalized Basic EPS | 45.57% | -1,471.17% | 74.73% | 53.44% | 57.40% |
| EPS Diluted | 53.98% | 53.36% | 82.58% | 71.54% | 72.52% |
| Normalized Diluted EPS | 45.62% | -48.13% | 79.95% | 62.83% | 65.12% |
| Average Basic Shares Outstanding | 107.88% | 116.68% | 137.35% | 167.66% | 209.73% |
| Average Diluted Shares Outstanding | 104.57% | 83.51% | 98.34% | 110.98% | 124.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | 1.00% | 1.00% |